Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancerMohammadhadi Khorrami, Anant Madabhushi, Vidya Sakar Viswanathan et al.|npj Breast Cancer|2023Cited by 13
Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)Veronica Mariotti, Hatem Soliman, Nuhad Ibrahim et al.|Cancer Research|2020Cited by 2
619TiP PIKALO-1: A phase I/II trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in PIK3CA-mutant (PIK3CAm) advanced breast cancer (ABC) and other solid tumors (Trial in Progress)Antonio Giordano, D. Juric, Alberto J. Montero et al.|Annals of Oncology|2025Cited by 0